explore -WSS

explore

author：knowledge 2025-10-02 18:46:33 - browse：72295

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

hotspot

WSS

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Maui funeral service workers on devastation of fires: 'I'm in shock'

Readers respond to H5N1 and livestock movements, and more

explore

explore

explore

Supreme Court strikes down use of affirmative action

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

United colonoscopy coverage change 'may cost lives,' doctors say

Big Tobacco's 'harm reduction': Is it for real, or a sham?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Activists slam private health insurers over coverage restrictions

NVIDIA and Google execs on the future of AI and drug discovery

hotspot

Second House panel advances two

Bird flu: Don't repeat Covid's 'health versus the economy' framing

After John Oliver segment, STAT readers share their opioid

Pharma budget tightening trickles down to Doximity

Some of the ways extreme heat will change life as we know it

Novo acquires Inversago for up to $1 billion

hotspot

Wikipedia

hotspot

leisure time